Stem Point Capital LP Nurix Therapeutics, Inc. Transaction History
Stem Point Capital LP
- $340 Billion
- Q2 2024
A detailed history of Stem Point Capital LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Stem Point Capital LP holds 203,273 shares of NRIX stock, worth $5.54 Million. This represents 1.25% of its overall portfolio holdings.
Number of Shares
203,273Holding current value
$5.54 Million% of portfolio
1.25%Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
67.3MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$186 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$120 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$109 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$106 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$98.7 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.28B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...